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The rapid and effective bone regeneration of large non-healing defects remains challenging. Bioactive
proteins, such as bone morphogenetic protein (BMP)-2, are proved their osteoinductivity, but their
clinical use is currently limited to collagen as biomaterial. Being able to deliver BMP-2 from any other
biomaterial would broaden its clinical use. This work presents a novel means for repairing a critical size
volumetric bone femoral defect in the rat by combining a osteoinductive surface coating (2D) to a
polymeric scaffold (3D hollow tube) made of commercially-available PLGA. Using a polyelectrolyte ﬁlm
as BMP-2 carrier, we tune the amount of BMP-2 loaded in and released from the polyelectrolyte ﬁlm
coating over a large extent by controlling the ﬁlm crosslinking level and initial concentration of BMP-2 in
solution. Using microcomputed tomography and quantitative analysis of the regenerated bone growth
kinetics, we show that the amount of newly formed bone and kinetics can be modulated: an effective and
fast repair was obtained in 1e2 weeks in the best conditions, including complete defect bridging, for-
mation of vascularized and mineralized bone tissue. Histological staining and high-resolution computed
tomography revealed the presence of bone regeneration inside and around the tube with spatially
distinct organization for trabecular-like and cortical bones. The amount of cortical bone and its thickness
increased with the BMP-2 dose. In view of the recent developments in additive manufacturing tech-
niques, this surface-coating technology may be applied in combination with various types of polymeric
or metallic scaffolds to offer new perspectives of bone regeneration in personalized medicine.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).3 parvis Louis Neel, F-38016,
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er Ltd. This is an open access artic1. Introduction
The treatment of large bone defects resulting from trauma, non-
union, tumor resections or craniofacial malformations remains
challenging. More than 500,000 bone fractures require bone grafts
in the USA among the 6.3million annually reported cases and result
in medical costs of $2.5 billion [1]. These conventional grafts, which
combine osteogenic cells and osteoinductive and osteoconductive
properties [2,3], are limited by donor-site morbidity, chronic
inﬂammation or the risk of disease transmission. Synthetic bonele under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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synthetic polymers [4], have been developed to mimic bones, but
they lack osteoinductive signals.
Growth factors are particularly interesting because of their
ability to target speciﬁc cellular receptors and actively trigger
various cellular processes [5]. Among those involved in bone
healing, bone morphogenetic protein (BMP)-2 is the most potent
bone inductor [6] and is involved in different phases of repair [7].
BMP-2 has been used in orthopedic and maxillofacial surgery since
2003 [8], but its use has been paired solely with collagen as the only
approved carrier. Unfortunately, the poor retention of BMP-2 by
collagen leads to its rapid clearance from implantation sites [9], and
thus, supra-physiological doses (at least a few mg) are required.
These issues have recently raised serious concerns regarding
ectopic bone formation, pain and cancer risk [10]. Thus, there is a
clear need to optimize the spatiotemporal delivery of BMPs using
new carrier materials [11].
BMPs may be delivered from two major strategies. The ﬁrst
consists in loading them in the “bulk” of space-ﬁlling materials,
such as porous scaffolds, mostly ceramics [11,12], biodegradable
polymers [13] and hydrogels as carriers [14e16]. Indeed, natural
polymers, polysaccharides and ECM proteins, such as hyaluronan
[17e19], heparin [20,21], ﬁbronectin and ﬁbrin [22], are of interest
because of their natural afﬁnities for BMPs. They can be used to
increase the retention of BMP-2 inside the bulk of the scaffolds [21]
or for injectable formulations [18,15]. For these space-ﬁlling com-
posite materials, the release of BMP is intrinsically linked to the
spatiotemporal degradation proﬁle of the scaffold or hydrogel.
The secondmajor strategy consists in functionalizing the surface
of scaffolds to trap and subsequently release BMPs directly from the
surface of scaffolds [23]. Surface coatings may potentially be
applied to a variety of scaffolds of different shapes and chemical
nature, including ceramics, metals, or synthetic polymers, thus
broadening the potential for clinical applications of BMP-2 by
adapting independently on one hand, the scaffold architecture and
on the other hand, the BMP-2 dose delivered locally via the surface.
To date, several methods have already been proposed to present
BMP-2 at the surface of scaffolds either by direct grafting of BMP-2
[23] or by indirect adsorption via hydroxyapatite [24,25] or bio-
polymers [20,26,27], thanks to their natural afﬁnities with BMPs.
However, direct grafting may be limited by the loss of BMP-2
bioactivity [23] and surface adsorption leads to low adsorbed
doses of BMP-2 [26,28]. Layer-by-layer ﬁlms made of hydrolytically
degradable polymers [29], polypeptides [30] or polysaccharides
into which BMPs are adsorbed by physical interactions [31]
constitute an interesting surface coating as their thickness can be
easily tuned and they can act as a nano-reservoir for BMP-2 mol-
ecules. Recently, we have shown, using poly(L-lysine) (PLL) and
hyaluronic acid (HA) polyelectrolyte ﬁlms as a carrier for BMP-2
[31], that ﬁlms deposited on ceramics and titanium implants are
osteoinductive in a rat ectopic model [32,33].
Here, our aimwas to repair a volumetric (3D) bone defect, which
was initially totally empty, by means of an osteoinductive poly-
electrolyte multilayer ﬁlm delivering tunable doses of BMP-2 from
the surface (2D) of a ﬁlm-coated PLGA scaffold. This cell-free
approach for the repair of a large bone defect and is an “in-situ
tissue engineering” approach, with the underlying ideas that i) the
growth factors delivered by the surface coating will actively trigger
the differentiation of precursor cells into bone cells and ii) the
spatial localization of the growth factors is provided by the un-
derlying 3D polymeric scaffold and will guide the architecture of
the subsequent tissue formation in the initially fully empty 3D
scaffold.
We designed a 3D hollow tube in PLGA, a scaffold material
widely used in maxillofacial surgeries [34] and orthopedics [35]that was custom-shaped to a critical-size femoral defect. By
modulating the dose of BMP-2 in the ﬁlm coating via the initial
loading concentration of BMP-2 and the controlled crosslinking of
the ﬁlm, we showed that bone healing can be very fast (1e2
weeks) and maturation inside the PLGA hollow tube can be opti-
mized from the absence of bone to excessive bone production.
Importantly, a distinct spatial volumetric organization of bone was
triggered by the BMP-2 ﬁlm coating, with trabecular bone forming
within the hollow tube and cortical bone forming around the
scaffold, the thickness of the cortical being dependent on the BMP-
2 dose.2. Experimental section
2.1. PLGA tube preparation and polyelectrolyte multilayer ﬁlm
(PEM) coating
0.25 mm thick 50  50 mm biodegradable Lactosorb sheets
(Biomet Microﬁxation, Netherland), made of 82% poly(L-lactic) acid
and 18% poly(glycolic) acid (PLGA, half-life¼ 6months according to
manufacturer data) were used for the in vitro and in vivo experi-
ments. Before the ﬁlm deposition, the planar sheets were trimmed
and thermoformed at ~80 C into tubes to ﬁt to 6 mm femoral
defects (Fig. 1A). To this end, they were placed in an air active heat
pack (Biomet Microﬁxation) for 10e15 s according to the manu-
facturer instructions. The surfaces of the PLGA tubes were
measured to be 1.31 ± 0.05 cm2 (means ± SEM).
The PEM ﬁlm was deposited using 0.5-mg/mL poly(L-lysine)
hydrobromide (PLL, 55 kDa, Sigma, France) and 1mg/mL hyaluronic
acid (HA, 360 kDa, Lifecore, USA) [33]. The ﬁlm crosslinking extent
was controlled by incubating the coated tubes in 10-, 30-, or 70-mg/
mL 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, Sigma,
France) and 11-mg/mL N-hydroxysulfosuccinimide (sulfo-NHS,
Sigma, France). BMP-2 was post-loaded in the PEM ﬁlms at 5, 25,
50, or 100 mg/mL, as described previously [31,33]. Finally, the
osteoinductive coated tubes were rinsed, dried, and stored at room
temperature until implantation.2.2. Characterization of PEM ﬁlms and quantiﬁcation of BMP-2
loading
Dry ﬁlm thickness was measured by using a Dektak XT (Bruker
Corporation) proﬁlometer. Three samples (PLL/HA)24 ﬁlms depos-
ited on silicon were scratched to create a physical step and three
measurements per sample were acquired with the software Vision
64® (v 5.4, Bruker Corporation, USA). Scans of 30 s over a length of
1000 mm were performed with a stylus of 12.5 mm in radius and a
force set to 1 mg. Thus, dry ﬁlm thickness is an average value of 9
measurements.
The air dried PEM ﬁlms coated on PLGA planar substrates were
imaged by scanning electron microscopy (SEM) using a FEI-Quanta
250 SEM-FEG in high vacuum at 15 keV using the Everhart-
Thornley detector.
The amounts of BMP-2 initially loaded into the PEM ﬁlms and
subsequently released after several washes with the Hepes-NaCl
buffer were determined as previously described (1) by ﬂuores-
cence spectrometry (TECAN Inﬁnite 1000, Austria) using 5% of
carboxyﬂuorescein labeled BMP-2 (BMP-2CF) as a tracer. Knowing
the total surface of the PLGA (see part 2.1), the total surface area of
the PEM ﬁlms was roughly estimated to be 2.6 cm2, with the in-
ternal and external sides of the PLGA tubes being coated by the ﬁlm.
This value was used to convert the initial and ﬁnal surface-
adsorbed amounts, GI and GR (mg/cm2), respectively, to absolute
amounts (mg).
Fig. 1. Experimental design of the in vivo experiments in rat femoral critical-size defect. (A) Procedure for the ﬁlm buildup on the PLGA membrane: the PLGA sheet is cut to the
appropriate size and molded into a hollow tube. The ﬁlm is built on the tube, crosslinked and post-loaded with BMP-2. The ﬁlm-coated membrane can be visualized by scanning
electron microscopy. Both EDC crosslinking and BMP-2 loaded amounts are adjustable parameters. A scanning electron microscopy side view of the ﬁlm-coated PLGA membrane
reveals the presence of the ﬁlm after scratching (white arrow). (B) Scheme of the critical defect with the PLGA membrane shaped as a hollow tube and ﬁxed with external ﬁxators
(plate and screws) and suture wires. (C) Post-operative view of the implanted PLGA tube maintained by suture wires.
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Murine C2C12 skeletal myoblasts (<25 passages, obtained from
the American Type Culture Collection, ATCC) were cultured in tis-
sue culture Petri dishes [32]. The bioactivity of BMP-2 on
C2C12 cells was determined by assaying the BMP-2 induced alka-
line phosphatase (ALP) expression, which is an early marker of
osteogenic differentiation. To this end, 90,000 cells in 1 mL of GM
were seeded on each PLGA sample (square of 1 mm2) in a 24-well
plate. After 3 days of culture, the GM was removed and the cells
werewashedwith PBS and lysed by sonication over 5 s in 500mL of
0.1% Triton-X100 in PBS. The ALP activity of these lysates was then
quantiﬁed using standard protocol [32] and normalized to the
corresponding total protein content, which was determined using a
bicinchoninic acid protein assay kit (Interchim, France).
2.4. In vivo critical-size defect in rat
All surgical procedures were reviewed and approved by the
ethics committee in animal experimentation of Grenoble (Protocol
229_ IAB-U823-VJ-03). A 6 mm critical-size rat femoral defect
model was chosen in this study because the non-healing nature of
this model is well established [36,37]. Female Wistar rats (Janvier,
St Berthevin, France) aged 53e67 days were anesthetized using
isoﬂurane and intraperitoneal injection of Ketamine Hydrochloride
at 100 mg/kg body weight and medetomidine (Axience, Pantin,
France) at 100 mg/kg body weight. All rats were operated on the
right femur only. The rat was positioned in left lateral decubitus on
a thermostatic heating plate to prevent hypothermia. The surgical
area was shaved and scrubbed with povidone iodine. The incisionwas made on the anterolateral thigh, from the relief of the major
trochanter to the knee. After the subcutaneous dissection, a lon-
gitudinal incision of the fascia lata muscle and a blunt dissection
through the septum between the vastus lateralis and biceps femori
were performed to expose the femur. A full-thickness diaphyseal
critical-sized segmental defect of minimum 6mm long was created
using a circular mini-saw under irrigation. The periosteum was
removed with the resected bone and on the remaining femoral
fragments. The femur was stabilized by a titanium plate with a
12 mm bridge, and 4 screws of 1.7 mm in diameter (Stryker, France)
associated with a distal and proximal 4/10 strapping steel wire
(Nichrominox, Lyon, France). A PLGA tube was placed around the
bone defect by overlapping to ~1 mm the femoral bone edges.
These tubes were studded by a non-absorbable 4/0 suture. The
wound was closed in a layered fashion by resorbable stitches. The
rats carried a buster collar for 48 h. Animals were given 0.1 mg/kg
buprenorphine subcutaneously every 12 h for the ﬁrst 24 h post-
surgery, and a tetracycline and trimethoprim sulfamethoxazole
antibiotics for 48 h (Sigma-Aldrich, France). Within 2e3 post-
operative days, the animals recovered a normal ambulation and did
not show any sign of pain or distress.
First, in a preliminary experiment, we screened 10 conditions
(n ¼ 2) using X-ray before selecting 5 conditions that were further
studied in larger groups (n ¼ 8 at least for each) for statistical
analysis (see Table 1 for all experimental conditions). Three controls
were performed: i) defect left with no implant to conﬁrm the
critical size of the defect (no PLGA tube, n¼ 3), ii) bare PLGA (n¼ 8),
iii) PLGAwith BMP-2 directly adsorbed at 25 or 50 or 100 mg/mL on
the PLGA tube (adsBMP-2, n ¼ 2 for each concentration). Each
implant was randomized, implanted and analyzed in a blind
Table 1
Experimental conditions and total number of rat per group studied. For conditions
only studied in the preliminary experiments, n ¼ 2. For all the 5 selected groups in
the subsequent experiment, the total number of samples per condition was n ¼ 8. In
addition to these BMP-containing conditions, two negative control groups were
added: i) defect left with no implant to conﬁrm the critical size of the defect (no
PLGA tube, n ¼ 3) and ii) bare PLGA (n ¼ 8).
Parameter crosslinking BMP-2 concentration in the loading
solution (mg/mL)
BMP5 BMP25 BMP50 BMP100
EDC10 2 2 þ 6 2 þ 6 2 þ 6
EDC30 2 2 þ 6 2 þ 6 e
EDC70 2 2 2 e
Control Ads BMP-2 on bare PLGA 2 2 2
M. Bouyer et al. / Biomaterials 104 (2016) 168e181 171manner, the PEM ﬁlms being macroscopically indistinguishable. All
analyses of experimental groups were made in a blind manner. In
the preliminary experiments, we noted that some rats presented
clinical hematoma after the ﬁrst 48 h post-surgery. In the subse-
quent experiments, during the ﬁrst 48 h, only rats that presented
with a large clinical hematoma had a percutaneous puncture while
those presenting with minimal clinical hematoma were not punc-
tured, such assessment being made in a blind manner with respect
to the experimental groups. After 8 weeks (56 days), the rats were
euthanized by intracardiac injection of Dolethal (Vetoquinol, Paris,
France) under gaseous anesthesia (isoﬂurane) and we reported the
rats that had a clinical hematoma and rats that were punctured
(Table 2). Plates and screws were then removed and the femurs
were harvested ﬁxed in 4% neutral buffered formalin (Sigma,
France) for at least 24 h at 4 C.
2.5. Radiographic and mCT analysis using a commercial apparatus
Assessment of bone formation was made by X-ray after 0, 2, 4, 6
and 8 weeks. These radiographies were performed under gaseous
anesthesia (isoﬂurane) on VivaCT 40 mCT (ScancoMedical, Brütti-
selen, Switzerland) using scout views (55 kV, 300 ms).
An X-ray score was calculated in a blind manner by two sur-
geons analyzing the radiographies following the score proposed by
Guldberg and coworkers [38]: (0) below half bone healing (1);
above half bone healing but still incomplete (2); complete repair of
the defect. The scores were ﬁtted with an exponential function:
X ray score ¼ Bmaxx½1 expðt=tÞ (1)
t is the characteristic time of bone regeneration (in days) and Bmax
is the plateau value (in a.u.).
After 8 weeks, mCT imaging using this commercial apparatus
(technique named hereafter CmCT) was performed on ﬁxed bones
using medium or high resolution scanner (70 kV, 114 mA, 42 mm
isotropic voxel size). Sagittal cross sections and 3D representationsTable 2
Presence of clinical hematoma, punctured hematoma and percentage of bone defect
increasing concentrations of BMP-2 from BMP5 to BMP100 and EDC30 groups at BM
indicates a minimal clinical hematoma, which thus was not punctured.
Groups Clinical hematoma
Bare PLGA 0%
EDC10 groups
BMP5 (n¼ 2) 0%
BMP25 0%
BMP50 12.5% (m)
BMP100 75%
EDC30 groups
BMP25 12.5% (m)
BMP50 0%weremade using the Osirix© software. The volume of interest (VOI)
was deﬁned as the total volume of newly formed bone between the
native bone ends. Contralateral femurs were used as internal con-
trols for each rat with the same number of slices for the VOI con-
cerned. The VOI was segmented by application of a global threshold
(386 mg HA/cm3) and a Gaussian ﬁlter (sigma 0.8, support 1) to
suppress the noise. Results were expressed as a bone volume ratio
by dividing the newly formed bone volume by the volume of the
internal control.
2.6. Histological analysis
The femurs were analyzed histologically after 8 weeks. After
osteotomies of both epiphyses, the femurs were transferred to a
68% nitric acid-based decalciﬁer (VWR International, Basan, France)
for 55e160 h depending on the bone hardness (felt with a surgical
clamp). Following parafﬁn processing, 5e7 mm thick mid-sagittal
sections were cut, pasted with albumin and stick-on (Labonord,
Templemars, France) and stained with Safranin-O/Fast-green
(Microm Microtech, Francheville, France), haematoxylin and eosin
(Diapath, Martinengo, Italy). The histological slices were read in a
blindmanner by a pathologist, who attributed a score based on four
criteria: (1) mesenchymal tissue, (2) ossiﬁcation points (3) cancel-
lous bone or (3) cortical bone. Thus themaximum total score was 9.
2.7. Synchrotron radiation micro-computed tomography (SRmCT)
The conditions that showed the best results in term of bone
regeneration (kinetics of bone growth and bone volume) were
further analyzed in greater detail using SRmCT at beamline ID19 at
the European Synchrotron Radiation Facility (ESRF, Grenoble,
France). Scans were performed with a 26.7 keV pink beam and
setting the sample-detector distance at 400 mm enabling to record
phase contrast. For each sample, 3800 projections were collected
over a range of 360. Images were reconstructed using Paganin's
phase retrieval method [39] followed by the standard Filtered Back
projection CT reconstruction algorithm. The Paganin method as-
sumes proportionality between the linear attenuation coefﬁcient
(m) proportional to the absorption index (b) and the refractive index
decrement (d), and the d/b ratio was set to 430. The 3D recon-
structed volume had an isotropic voxel size of (3.5 mm)3. The vol-
ume of interest (VOI) was determined in a similar fashion as
described for the conventional mCT. The newly formed bone tissue
was segmented by applying a global gray level threshold and two
different bone tissues were clearly observed: cortical-like bone (Ct-
bone) forming a compact shell of bone tissue outside the PLGA tube
and trabecular-like bone (Tb-bone) forming a reticulated bone
tissuemainly inside the PLGA tube. Ct-and Tb-bonewere separately
extracted based on their morphology using a segmentation work-
ﬂow based on 3D region growing (software Avizo, FEI). 3Ds that were completed healed in the case of the bare PLGA, EDC10 groups with
P25 and BMP50. (n ¼ 8 for all groups expect for the BMP-2 group n ¼ 2). (m)
Punctured hematoma Complete bone healing
0 0%
0 0%
0 62.5%
0 100%
6 100%
0 50%
0 100%
M. Bouyer et al. / Biomaterials 104 (2016) 168e181172renderings showing the homogeneity of cortical bone and the
trabecular network organization were obtained with the software
VGStudio MAX (Volume Graphics GmbH).
Bone volume (BV) and total volume (TV) were determined for
each VOI (i.e. Ct and Tb VOIs) by counting the number of non-zero
pixels in binarized images and converting them to volumetric units
(mm3) using the voxel size. The mean thickness of bone structure
was calculated by deﬁning the 3D thickness at each point as the
diameter of the largest sphere that can ﬁt within the structure [40].
The connectivity of the trabecular network (b1) was derived from
the Euler number (c) and was calculated automatically using an in-
house program based on the method described by Odgaard [41]:
b1 ¼ b0 þ b2  c (2)
where b0 and b2 respectively correspond to the number of con-
nected components and cavities.
The density of connectivity (expressed in mm3) was then
deﬁned as b1/TV where TV is the Total Volume as explained above.
These images were also used to quantify the mass density (r)
within bone tissue thanks to the theoretical relationship linking the
refractive index decrement to the mass density [42]:
d ¼ 1:3$106$r$l2 (3)
r (g/cm3) corresponds to the mass density of the bone structure, l
(Å) corresponds to the selected wavelength of synchrotron
radiation.
2.8. Statistics
Sigmaplot (Systat Software Inc) was used for all analyses. Non-
parametric data were presented by median and interquartile
range. Differences between groups were assessed by the Mann-
Whitney U test for independent samples, with pairwise compari-
sons made by Bonferroni correction (multiple groups), and by the
Wilcoxon paired test for paired samples. Parametric data were
presented by mean and standard error of the mean (SEM). c-
squared analyses with individual comparisons were made by
Fisher's exact test. A P value < 0.05 was considered signiﬁcant.
3. Results
3.1. Tunable loading of bioactive BMP-2 in polyelectrolyte ﬁlm-
coated PLGA membranes
We used a commercially available Lactosorb® PLGA membrane
trimmed and thermoformed at approximately 80 C into hollow
5 mm  8 mm tubes to ﬁt rat femoral defects (Fig. 1). The PLGA
tubes were coated with a PEM ﬁlm made of 24 alternating layers of
PLL and HA. Such (PLL/HA) ﬁlms are known to growth exponen-
tially with the number of deposited layer pairs from few tens of
nanometers to several micrometers (hydrated thickness), which
enable to modulate their thickness [43]. They contain a major
amino-acid residue lysine, which bears amine groups and hyalur-
onan, which is a major component of the cellular coat [44] and of
extracellular matrices [45]. As the concentration of the poly-
electrolytes can inﬂuence ﬁlm growth, we used previously estab-
lished conditions for the ﬁlm buildup (PLL at 0.5 mg/mL and HA at
1 mg/mL) [31].
The PEM ﬁlmwas crosslinked using tunable concentrations of 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) as a zero-
length crosslinker. The ﬁlms were named EDC10, EDC30, and
EDC70 according to the crosslinker concentration used. Finally, the
ﬁlms were post-loaded with BMP-2 [31] at various concentrationsranging from 5 to 100 mg/mL In this previous study, we already
proved that there is an interaction between HA and BMP-2 at pH 3
(acidic) and pH 7.4 (physiological) [31], which contribute to explain
the observed high afﬁnity of BMP-2 for the PEM ﬁlms. Hereafter,
the ﬁlms are referred to as BMP5, BMP25, BMP50, and BMP100 to
indicate the concentration of BMP-2 used. As observed by scanning
electron microscopy after scratching the ﬁlm, the PEM ﬁlm fully
coated the PLGA surface (Fig. 1A). Atomic force microscopy (in
liquid) and proﬁlometry (in the dry state) were used tomeasure the
ﬁlm cross-sections to quantify the hydrated and dry ﬁlm thick-
nesses (6 mm ± 0.6 mm versus 870 ± 55 nm, respectively). Thus, the
ﬁlm thickness decreases by about 7 fold upon drying. For the in vivo
study, the dry ﬁlm-coated tubes were inserted into 6-mm long
critical-size defects in rat femurs for 8 weeks (Fig. 1B and C).
The amount of BMP-2 initially loaded into the PEM ﬁlms and the
percentage of released BMP-2 in vitro after several washes with a
physiological (HEPES-NaCl) buffer were determined by ﬂuorescent
spectrometry using carboxyﬂuorescein-labeled BMP-2 (BMP-2CF)
as a tracer [31]. The total amount of BMP-2 loaded in the ﬁlms
(initial adsorbed amount Gi in mg) was dependent on the initial
BMP-2 concentration in the loading solution and not on the EDC
crosslinking (Fig. 2A). Gi varied from 1.5 to 34.6 ± 0.8 mg as the BMP-
2 concentration increased from 5 to 100 mg/mL. However, the
percentage of released BMP-2 and the absolute released amounts
(GR) were dependent on the extent of crosslinking (Fig. 2A and B).
The release mostly occurred during the ﬁrst 5 h and was higher for
the EDC10 > EDC30 > EDC 70 (respectively 80e91%, 20e52% and
0e22%). Consequently, the GR was consistently higher for the
EDC10 ﬁlms than the EDC30 and EDC70 ﬁlms. GR varied between
0 and 26.8± 0.8 mg depending on the extent of EDC crosslinking and
BMP-2 dose. The bioactivity of the ﬁlm-coated PLGA membranes
was assessed using an ALP activity assay in C2C12 skeletal myo-
blasts (Fig. 2C), an acknowledged cellular model to assess BMP-2
bioactivity in vitro [46]. The ALP activity increased in a dose-
dependent manner and reached a plateau value for BMP25 doses,
except for EDC10 ﬁlms in which the ALP activity decreased at a
BMP100 dose. The control ALP values for cells directly grown on the
PLGA membranes when BMP-2 was delivered in solution (sBMP-2,
1.7 ± 0.1, blue line) or adsorbed (adsBMP-2, 0.9 ± 0.2, red line) on a
bare PLGA membrane at the highest BMP-2 concentration (100 mg/
mL) were systematically lower and similar to the activity of a ﬁlm
loaded at BMP5. We further veriﬁed the thermal molding of the
PLGA tube after ﬁlm deposition did not affect the bioactivity of the
BMP-2-loaded PEM ﬁlm (Fig. S1).
3.2. BMP-2 dose inﬂuences the bone repair kinetics
The femoral critical-size defect in the rat is a well-established
model [44] and was used here to test ﬁlm-coated PLGA tubes. To
optimize bone regeneration, we performed a preliminary experi-
ment and initially screened in ten different conditions (n ¼ 2),
corresponding to four increasing concentrations of BMP-2 (BMP5,
25, 50, or 100) and three increasing crosslinking levels (EDC10, 30
and 70) (Table 1). Indeed, our previous data showed that the
highest dose of BMP-2 (EDC10/BMP100) exhibited an osteoinduc-
tive capacity in a rat ectopic model [32].
Conventional mCT (CmCT) acquisitions acquired 8 weeks after
surgery enabled estimating the capacity of bone repair for the PEM
coatings on PLGA tubes (Fig. 3) and for the different control con-
ditions (Fig. S2). The negative control groups (empty defect; PLGA
tube alone; and BMP-2 adsorbed at increasing concentrations on
bare PLGA) showed no callus or bone formation throughout the
follow-up period (Fig. S2 and Table 2). All BMP groups exhibited
bone regeneration (Fig. 3), whatever the crosslinking of the ﬁlm,
except the BMP5 group, which consistently showed very low bone
Fig. 2. In vitro evaluation of BMP-2 loading, release and bioactivity as functions of BMP-2 initial loading concentration and ﬁlm crosslinking extent (EDC). (A) BMP-2
incorporated amounts (GI, mg), % of BMP-2 released and released amount remaining after 7 days of in vitro release (GR, mg) as a function of the initial BMP-2 concentration in
the loading solution and for different crosslinker concentrations (EDC10, 30 and 70). (B) BMP-2 release proﬁles in physiological buffer as a function of time over 8 days, depending
on the ﬁlm cross-linking extent. Data represent the means ± SEM of 3 experiments. (C) In vitro ALP bioactivity of BMP-2-loaded ﬁlms coated on PLGA membranes. Two controls were
performed: BMP-2 adsorbed onto a bare PLGA membrane (red line “bBMP-2”) and BMP-2 added in the GM for cells seeded directly on bare PLGA membranes (blue line “sBMP-2”).
Data represent the means ± SEM of 2 experiments (3 samples per experimental condition). (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
M. Bouyer et al. / Biomaterials 104 (2016) 168e181 173regeneration without total healing of the defect. A continuous
callus composed of “trabecular-like” bone (indicated by *) inside a
thick “cortical-like” bone (indicated by a white arrow) was visible.
For the EDC10/BMP100 group, hematomas appeared within 24 h
after surgery and formed a calciﬁed bony shell after 8 weeks.
We next repeated the experiments with more rats per condition
(Table 1) to quantitatively assess the effects of BMP-2 concentra-
tions (BMP25 to 100) and EDC crosslinking levels (EDC10 and
EDC30) (Fig. 4). We did not further studied the BMP5 groups
because of their poor regenerative capacity. We also excluded the
EDC70 groups because our previous data showed lower long-term
ﬁlm stability and an increased loss of bioactivity upon storage [33]
than did the EDC10 and EDC30 ﬁlms. Thus, in total, we continued
with 5 experimental groups. The presence of clinical hematoma
two day after surgery and the rats that required a percutaneous
puncture were systematically noted and reported (Table 2). In
Table 2, the percentage of bone healing is also systematically re-
ported based on X-ray analysis. For the BMP25 group, bone healing
was complete in 50e62.5% of the cases in comparisonwith 100% for
BMP50 and BMP100. The BMP50 groups had hematomas in fewer
than 12.5% of cases, whereas 75% of BMP100 samples presented
hematomas. Their presence was signiﬁcantly associated with the
BMP100 condition (P < 0.01, Fisher test). Only BMP100 group
showed large hematoma that required percutaneous puncture to
avoid the formation of calciﬁed bony shell like in the preliminaryexperiment. Others groups were not punctured and after 8 weeks
no group showed calciﬁed bony shell (Fig. 4A and Table 2).
The ratio of newly formed bone relative to a reference volume of
healthy bonewas quantiﬁed at 8 weeks by CmCT (Fig. 4B and C). The
bone volume ratio increased with increasing BMP concentration,
and the bone volume ratios for the BMP25, BMP50 and BMP100
groups were signiﬁcantly different than the control group but were
not signiﬁcantly different among themselves. The EDC crosslinking
level did not signiﬁcantly inﬂuence the bone volume ratio because
the BMP25 and BMP50 groups on EDC30 ﬁlms exhibited levels
similar to those of their EDC10 counterparts (Fig. 4C).
The ratio of newly formed bone relative to a reference volume of
healthy bone was quantiﬁed at 8 weeks by CmCT (Fig. 4B). The bone
volume ratio increased with increasing BMP concentration, and the
bone volume ratios for the BMP25/EDC10, BMP50/EDC10, BMP50/
EDC30 and BMP100/EDC10 groups were signiﬁcantly different from
the control group but were not signiﬁcantly different among them-
selves (marked by #). The EDC crosslinking level did not signiﬁcantly
inﬂuence the bone volume ratio since the BMP25 and BMP50 groups
on EDC30 ﬁlms exhibited similar levels to those of their EDC10
counterparts. To note, the bone volume ratio for the BMP5/EDC10
and for the BMP25/EDC30 group was not signiﬁcantly different from
the control group (marked by NS). In addition, the BMP100/EDC10
group showed a signiﬁcantly higher bone volume ratio than the
BMP5/EDC10 and BMP25/EDC30 groups (marked by x) (Fig. 4B).
Fig. 3. CmCT images at 8 weeks obtained for increasing EDC crosslinking (EDC10, EDC30 and EDC70) and BMP-2 doses from 5 to 100 mg/mL. Sagittal cross-sections are shown
for the 10 pre-screened conditions (see Table 1). All EDC5 conditions lead to an inappropriate bone formation and are marked by a red cross. Those that lead to a satisfactory bone
regeneration are marked by a green V sign. The EDC10/BMP100 condition is marked by an orange V sign as it lead to a bone shell formation if the hematomawas not punctured. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
M. Bouyer et al. / Biomaterials 104 (2016) 168e181174To quantify the bone repair kinetics, an X-ray score was calcu-
lated for the EDC10 and EDC30 conditions based on X-ray images
acquired every 2 weeks during the follow-up period (Fig. 4C) This
score was used to calculate a plateau value (Bmax) and a charac-
teristic bone-healing time scale (t) by ﬁtting an exponential
function to the experimental data, for the conditions inwhich bone
growth was observed. The scores steadily increased before reach-
ing a plateau, Bmax, and were higher for the BMP50 and BMP100
groups. The characteristic time t was approximately 3 times lower
for the BMP50 (7.9 ± 0.4) and BMP100 groups (6.4 ± 0.9 days) than
the BMP25 group (18 ± 2.3). Quantitatively similar kinetic curves
were obtained for the EDC30 ﬁlms loaded with the BMP25 and
BMP50 doses, with Bmax and t values similar to those of the EDC10
(7.9 ± 0.3 for BMP50 and 15.4 ± 6.5 for BMP25, respectively,
Fig. 4C).These data showed that the BMP-2 dose delivered from the PEM
coating signiﬁcantly inﬂuenced the repair kinetics of the bone
defect and that this BMP-2 dose dependence was observed inde-
pendently of EDC crosslinking levels.
3.3. Histological examination reveals the presence of maturing
trabecular and cortical bones
A histological examination provided information on the repair
process (Fig. 5). There was no sign of foreign body reactions, as
evidenced by the absence of inﬂammatory cells. The PLGA mem-
brane (T) was still visible (its half-life is approximately 6 months).
In the bare PLGA group, the tissue was characteristic of a non-union
with abundant mesenchymal tissue (m) inside the tube and a few
ossiﬁcation points (o) without callus (Fig. 5A). In the ﬁlm-coated
Fig. 4. Quantitative analysis of bone regeneration by X-ray and CmCT. Quantitative analysis of bone regeneration by X-ray and CmCT. (A) Representative 3D CmCT re-
constructions taken at 8 weeks after implantation for EDC with increasing doses of BMP-2 (BMP5 to BMP100) and control PLGA (scale bars, 5 mm). (B) Box plot representation of the
bone volume ratio at 8 weeks (n ¼ 8, except for BMP5/EDC10 with n ¼ 2) for the EDC10 and EDC30 ﬁlms with increasing BMP-2 doses from BMP5 to BMP100. BMP25 groups are in
pink, BMP50 in green and BMP100 in blue (for simpliﬁcation of the X-axis, the EDC is abbreviated by E). All groups were compared to the PLGA group. *P < 0.05, **P < 0.01, #
indicates no signiﬁcant difference between pairs, x indicates signiﬁcant difference (P < 0.05) compared to BMP100 group, ns indicates no signiﬁcant difference compared to PLGA
group (pairwise Mann-Whitney U test) (C) X-ray scores calculated from X-ray images as a function of time and corresponding exponential ﬁts to the data (colored lines) for EDC10
(D) and EDC(30) groups. The plateau value (Bmax), characteristic time t (days) deduced from the ﬁts and ﬁt quality R are given in the corresponding tables. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
M. Bouyer et al. / Biomaterials 104 (2016) 168e181 175PLGA group (Fig. 5B), there was a periosteal callus bridging the gap.
The pattern was different between the outside and inside of the
tube: a regenerated cortical (Ct) bone was observed outside andcancellous bone (Cn), and a small amount of mesenchymal tissue
was found inside. Imaging at higher magniﬁcation outside the tube
revealed that the cortical bone was approximately 200e400 mm
Fig. 5. Histological analysis. Representative bone tissue cross-sections of (A) control PLGA and (B) ﬁlm-coated PLGA at 8 weeks post-implantation. (A) The PLGA tube (T) was found
between the two femoral edges: (A) in mesenchymal tissue (m) and at the ossiﬁcation point (o). In contrast (B), cortical bone (Ct) and cancellous bone (Ca) with bone marrow (bm)
were found outside and inside the ﬁlm-coated PLGA tube, bridging the initial defect. (C) Corresponds to a larger magniﬁcation of the black box in (B); (D) to a larger magniﬁcation of
red box in (C) with visible blood vessels (v); (C', D') are the corresponding polarized light micrographs showing the birefringence of collagen strands. (E) Magniﬁed view of
trabecular bone, corresponding to green box in (B), in which bone marrow is present. (F) Magniﬁed view of the tube/tissue interface in (C) with adhesive cells (c) observed on the
ﬁlm-coated PLGA. Scale bars are as follows: (A, B): 800 mm; (C, C'): 400 mm; (D, D', E): 80 mm; (F): 20 mm. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)
M. Bouyer et al. / Biomaterials 104 (2016) 168e181176thick with well-organized blood vessels (Fig. 5C and D), showing
that vascularization is present in the regenerated bone. On these
sections, mineralized collagen strands and the PLGA tube were also
clearly visible under polarized light (Fig. 5 C' and D'). Inside the
tube, normal trabeculae (Tb) with bone marrow (bm) between two
cortical layers were present, similar to cancellous bone (Fig. 5E). A
few cells were in close contact with the surface of the ﬁlm-coated
PLGA tube (Fig. 5F). The histological score, which was determined
by a blinded pathologist, was signiﬁcantly higher for the BMP-
loaded ﬁlms than the control PLGA group (Fig. S3). Higher resolu-
tions imaging inside cortical bone and mesenchymal tissue [47]
revealed the presence of blood vessels inside the regenerated
bone (Fig. 6). The vessels can clearly be identiﬁed by the presence of
red blood cells with a characteristic discoidal shape [48] in their
lumen and of endothelial cells (ec, indicated by black arrows) lining
along the vessel walls (Fig. 6A and B). In addition, the imaging of
PLGAwith microscopy (Fig. 6C) and polarized microscopy (Fig. 6C'),
where its surface is indicated by a red line, reveals its semi-
crystalline structure by polarized microscopy. This dual observa-
tion also highlights a continuous thin line at its surface, which is
only visible by microscopy (Fig. 6C, yellow arrows) and not under
polarized light (Fig. 6C'). This line is indicative of the presence of the
polyelectrolyte ﬁlm coating at the PLGA surface (Fig. 6C).
All observations were consistent with a lack of bone tissue in the
control PLGA group and with maturing and vascularized new bone
tissue in the case of the BMP-2-loaded ﬁlms.
3.4. Spatial organization and BMP-2 dependence of bone formation
revealed by synchrotron radiation mCT
Having demonstrated that bone regeneration occurred both
inside and outside the PLGA tube, we next examined the spatial
organization of bone tissue using high-resolution SRmCT (Fig. 7).
We pooled the BMP25 and BMP50 conditions, regardless of the EDC
crosslinking level (10 and 30), because EDC did not have a major
inﬂuence on bone repair (Fig. 4). As a compact shell similar to
cortical (Ct) bone was clearly observed outside the PLGA tube,
whereas a reticulated bone tissue similar to trabecular (Tb) bonewas mainly found inside the PLGA tube (Fig. 7A), independently of
the BMP-2 dose, we decided to segment the newly formed into
distinct Ct and Tb bones. This was conﬁrmed by the higher mass
density of Ct than Tb bones (Fig. 7B). Notably, after 8 weeks, this
bone has formed everywhere inside the initially fully empty PLGA
tube, even if BMP-2 was delivered at the tube surface. We observed
that the Ct bone was more homogeneous along the length of the
defect in the BMP50 group than in the BMP25 group (Fig. 7A). The
trabecular networkwas alsomore established inside the PLGA tube.
Moreover, the total bone volume (i.e., the sum of the volumes of the
Ct bone and the Tb bone) was higher for the BMP50 group (P¼ 0.04,
Mann-Whitney U test, Fig. 8A). In contrast, the amount of Tb bone
did not signiﬁcantly vary with the BMP-2 dose (Fig. 8B). The in-
crease in total bone volume was rather attributed to a signiﬁcant
increase in Ct-bone volume and Ct-thickness (Fig. 8C and D). The
connectivity of the Tb bone was not signiﬁcantly different for the
two groups (Fig. 8E), but the Tb thickness decreased for the BMP50
group (P ¼ 0.13, Mann-Whitney U test) (Fig. 8F).
These data showed that the BMP-2 dose lead to spatially-
distinct Tb and Ct bones and that the BMP-2 dose also had a sig-
niﬁcant inﬂuence on the Ct bone.
4. Discussion
Here, we showed that a volumetric critical size defect that was
initially empty inside the PLGA tube can be repaired by the mere
presence of an osteoinductive surface coating. Our data further
showed the key role of the PEM ﬁlm as a BMP-2 carrier because the
bone-regeneration kinetics and the type of newly formed bone
were dependent on the BMP-2 dose. The negative controls with
bare PLGA, in the presence or absence of adsorbed BMP-2, showed
the robustness of the rat femoral defect model (Fig. 4 and S2). Here,
the PLGA tube served as a physical andmechanical support scaffold
for the osteoinductive ﬁlm. We demonstrated that BMP-2
remained active after the thermal molding of PLGA (Fig. S1),
which indicates that, for future clinical applications, the ﬁlm could
ﬁrst be deposited on the membrane before molding to the desired
shape.
Fig. 6. Histological observations of vascularization of regenerated bone tissue and of PLGA/tissue interface. High resolution histological observations reveals the presence of
numerous vessels (v) in the regenerated bone: (A) cortical (Ct) bone and (B) mesenchymal tissue (m); The vessels (v) can clearly be identiﬁed by the presence of endothelial cells (ec,
indicated by black arrows) lining along the vessel walls and by red blood cells (r) with their characteristic discoidal shape and absence of nucleus. (C,C') Imaging of PLGA/tissue
interface of the same zone with optical microscopy (C) and polarized light (C'). Polarized light shows the birefringence of PLGA, which is due to its semi-crystalline structure. The
PLGA surface is indicated by a red line. To note, the PLGA surface appears diffuse when observed by polarized microscopy (C') whereas a thin continuous line is visible in (C, orange
arrows). This continuous lines corresponds to the polyelectrolyte ﬁlm coating at the PLGA surface (with a thickness of only few mm). (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 7. High-resolution morphological analysis of bone regeneration using SRmCT at 8 weeks after implantation. (A) Representative transversal and sagittal cross-sections of 3D
SRmCT reconstructions of ﬁlm-coated PLGA tubes at BMP-2 doses of BMP25 and BMP50 (scale bars, 1 mm). (B) Bone mass density of Ct-bone and Tb-bone as determined by SRmCT.
Data are presented by boxplot for all samples pooled together, irrespective of the EDC or BMP-2 dose (n ¼ 12). **P < 0.01 (Wilcoxon paired test).
M. Bouyer et al. / Biomaterials 104 (2016) 168e181 177The novelty of the present study ﬁrst resides in the combination
of a 2D bioactive coating, which can deliver tunable doses of BMP-2,
with a 3D scaffold, which provide the necessary template for the
ﬁlm. Second, it resides in the fact that we bring here new experi-
mental results showing the capacity of the 2D ﬁlm/3D hollow
scaffold to repair a critical-size bone femoral defect, with the for-
mation of vascularized cortical and cancellous bone inside the
initially empty scaffold and at its surface. Basically, a new bone isformed in an initially fully-empty spacewith solely a hollow tube as
initial mechanical support. In addition, we showed that the quality
and amount of bone formed depends on the dose of BMP-2 deliv-
ered by the 2D surface coating.
We adapted the BMP-2 dose delivered from the PEM surface
coating by varying the BMP-2 loading concentration and the EDC
crosslinking level. The initial loading amounts in the ﬁlms were
tuned by controlling the BMP-2 concentrations, whereas the release
Fig. 8. Bone volumes quantiﬁed using SRmCT. Data are presented by boxplots at 8 weeks after implantation for ﬁlms loaded with BMP25 or BMP50, the EDC groups being pooled
together (n ¼ 6 for each BMP concentration). (A) Total bone volume. (B) Tb-bone volume. (C) Ct bone volume and (D) Ct thickness. (E) Connectivity and (F) trabecular thickness in Tb
bone. *P < 0.05, **P < 0.01; ns, not signiﬁcant (Mann-Whitney U test).
M. Bouyer et al. / Biomaterials 104 (2016) 168e181178proﬁles weremodulated via the extent of crosslinking (Fig. 2). In our
previous study, we already proved that there is an interaction be-
tween HA and BMP-2 both at pH 3 (acidic conditions) and at pH 7.4
(physiological conditions) [31], which contribute to explain the
observed high afﬁnity of BMP-2 for the PEM ﬁlms. Film crosslinking
is expected to modulate ﬁlm nanometer scale porosity, a more
crosslinked thus interconnected network having smaller pore size.
Thus, the increased level of ﬁlm crosslinking is consistent with the
observed decrease in BMP-2 release (EDC10 > EDC30 > EDC70 in
terms of released amount). Regarding the underlying mechanism
driving BMP-2 release from the ﬁlm in vivo, we may draw some
hypothesis. The hydrated and dry ﬁlm thicknesses are 6 mm± 0.6 mm
versus 870 ± 55 nm, respectively, which corresponds to a 7 fold
decrease in thickness upon drying of the ﬁlm (i.e. the ﬁlm shrinks).
Thus, one may anticipate that a “sponge” effect is occurring upon
implantation of the dry ﬁlm-coated scaffold and contact with bio-
logical ﬂuids. The rehydration will induce ﬁlm swelling and,
consequently, BMP-2 release. Here again, low crosslinked ﬁlms
(EDC10) are expected to release more BMP-2. Second, in view of the
nature of PLL and HA as biopolymeric components of the ﬁlms and
the presence of various enzymes in vivo, including hyaluronidase
[49], we anticipate that the ﬁlm should be biodegradable. Here
again, a less crosslinked network should be more easily degradable,
which was already shown to be the case for crosslinked chitosan/HA
ﬁlms [50]. Thus, we may hypothesize two different and comple-
mentary mechanisms for BMP-2 release: i) ﬁrst, a release due to the
initial ﬁlm-swelling; and ii) second on a longer-term, a release
associated to ﬁlm biodegradability. Technically, ﬁlm biodegrad-
ability in vivo is extremely challenging to assess in view of the
roughness of PLGA, the micrometer thickness of the hydrated ﬁlm
(Fig. 6), and the poor contrast of the ﬁlm and PLGA. Indeed, SEM
images in vitro (e.g. in easier imaging conditions) enabled to reveal
the presence of the ﬁlm only after scratching it (Fig. 1) and in vivo
histological imaging revealed, at the micron scale, that the ﬁlm isstill at present at the PLGA surface after 2months but cannot be used
to investigate its nanometer scale biodegradability.
We showed that the kinetics of bone regeneration and the
volume of newly formed bone depended on the delivered dose of
BMP-2 (Figs. 3 and 4). However, an excessive BMP-2 dose (BMP100)
was associated with the presence of large hematomas and if not
punctured, calciﬁed shell formation. For lower BMP-2 doses, only
minimal clinical hematoma could occur (one rat out of 8) but these
were spontaneously resorbed and did not lead to calciﬁed shell
formation. Our data are in agreement with previous studies using
approved collagen sponges BMP-2 delivery systems [51e53], with
the occurrence of encapsulated hematomas at high doses of BMP-2
[51] and with our recent data of transient bone loss around ﬁlm-
coated titanium and poly(etheretherketone) screws (with the
dose EDC10/BMP100) implanted in the rabbit femoral condyle [54].
Based on the amounts of BMP-2 incorporated in the ﬁlms (Fig. 2)
and on our results that show bone formation between BMP25 and
BMP50 irrespective of EDC crosslinking (Figs. 3 and 4 and Table 2),
we can estimate the minimal BMP dose required to induce com-
plete repair of the femoral bone defect. These thresholds are be-
tween the highest released amount (6.5 mg) for the BMP25 group
(corresponding to EDC10/BMP25) and the lowest released amount
(7.8 mg) for the BMP50 groups (corresponding to EDC30/BMP50)
(Fig. 2). The BMP-2 concentration in the loading solution amount
was found to be more inﬂuential on the bone volume and growth
kinetics than the EDC crosslinking (Fig. 4), highlighting the greater
role of the initial total loaded of amount BMP-2 (Gi), which is
globally similar for all EDC conditions, in comparison to the initially
released amount (% rel and GR), which is mostly dependent on the
EDC crosslinking level (Fig. 2). Importantly, the kinetics of bone
regeneration depended on the BMP-2 dose and was extremely
rapid for BMP50 and 100 with t of 7 days (Fig. 4).
To the best of our knowledge, only one study by Guldberg et al.
[14], who used a similar femoral defect model, has focused on the
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caprolactone tube ﬁlled with an alginate gel as the BMP-2 carrier.
Thus, the gel was ﬁlling the entire volume of the tube and was not a
surface coating. By testing six doses from 0 to 5 mg, they found that
bone volume and connectivity were not linearly correlated with the
BMP-2 dose and further observed a reduced response beyond 1.0 mg
for alginate and a different dose response for the collagen sponge.
In their study, bone slowly formedwith continued growth for 8 and
12 weeks [14] and the kinetics of bone growth was independent of
the BMP-2 dose. The differences in the kinetics and BMP-2 dose
response between their study and ours may be due to the different
BMP-2 presentations: in the bulk of the alginate gel ﬁlling a porous
tube [14] versus direct delivery by the surface of a hollow tube in
our study.
Using a similar approach of composite scaffold, made of porous
polypropylene fumarate (PPF) incorporating gelatin micro-
particles (GMP), which are crosslinked with glutaraldehyde and
serve as carriers for VEGF and BMP-2 release, Mikos et al. [55]
studied the combined inﬂuence of BMP-2 and VEGF on bone
repair in a rat calvarial defect. They found a dose-dependent
decrease in bone repair with the BMP-2 dose, which could not be
reversed by the addition of VEGF. It is interesting to note that, in a
system where BMP-2 and VEGF release are intrinsically linked to
the biodegradability of the composite carrier (GMP and PPF), the
addition of a second growth factor (VEGF) did not improve the
repair process. This highlights the interest for optimizing simple
systems (i.e. less components) and not necessary adding
complexity in a system.
Regarding surface coatings, Hammond et al. [56] recently
studied the regenerative capacity of hydrolyzable PEM coatings
loaded at two BMP-2 doses (0.2 and 2 mg) deposited on circular and
planar PLGA membranes in a rat calvarial bone defect model. The
calvarial defect can considered as a “surfacic” and planar bone
defect and, because of the proximity of dura mater providing stem
cells and growth factors, was found to enable bone repair after 8
weeks, even in the absence of growth factors [53]. In this model,
there was no signiﬁcant difference between two BMP-2 doses or
when PDGF was co-delivered with BMP-2 [56] but alendronate
added as a supplementary ingredient improved rate and quality of
bone repair. PEM coating with two active ingredients [56], similarly
to hydrogels that deliver two active growth factors [57], showed
improved bone regeneration capacities but may bemore difﬁcult to
translate clinically. In fact, clinical translation requires that all
components of the ﬁnal drug will want quantifying in vivo in urine
and feces to show effective half-life and clearance [58].
Our CT data and histological observations (Figs. 4e8) showed
that after 8 weeks, the newly formed bone was in a matured state
composed of both cortical and trabecular bones with blood vessels
and mineralized collagen. Vascularization plays a critical role in
bone function and repair [59] because it permits communication
between cells and the mineralization of the extracellular matrix.
The lower mass density of Tb bone calculated from all samples
(Fig. 6B) was in line with reported increased, metabolically active
states with Tb remodeling [60]. The spatial 3D organization of the
bone tissue was likely facilitated by the empty PLGA tube, which
provided a 3D space for bone regeneration both inside and outside
the tube. Indeed, he the mass density of Ct-bone was higher for Tb
(Fig. 6B), and cortical thickness of the BMP50 group was great than
that of BMP25 (Fig. 7C). However, these measurements were not
directly observed in the current study. Although the connectivity
values were not different, the trabecular bone was thinner for the
BMP50 group (Fig. 7E). We hypothesize that over time and under
the inﬂuence of mechanical stimulus, trabeculae may disappear to
form normal diaphyseal bone devoid of trabecular bone and
become essentially composed of thick cortical bone.In the context of this regenerated volumetric bone defect, what
about the potential biodegradation of the supporting PLGA scaffold
itself? According to the technical datasheet provided by the
manufacturer, the half-life of Lactosorb is 6 month [61]. Biodegra-
dation occurs by hydrolysis. At 2 months (our time point), 95% of it
mass and 70% of its strength are remaining. In vitro data indicate
that, after 33 days of exposure to buffer, there was no change in
physical appearance, dimensions or shape of Lactosorb screws [62].
Strength loss proﬁles also demonstrated peak strength retention
(ﬂexural and shear) for about 8 weeks [63]. In vivo, no change in
shape of Lactosorb plates and screws was seen and a non-
inﬂammatory layer of surrounding ﬁbrous tissue was present
[64], the safety and beneﬁts of this material being conﬁrmed on the
long-term [35]. Our histological observations and SRmCT images are
consistent with these previous results as the PLGA tube is clearly
still present, with cells in contact with it (Fig. 4) and with no sign of
biodegradation (Fig. 6, PLGA tube visible by birefringence micro-
scopy and Fig. 7- tube visible in gray color by SR-mCT). It is also clear
that PLGA is coated with the ﬁlm (Fig. 6) and that bone is in contact
with the 3D hollow tube (Fig. 5). Indeed, the presence of the
polyelectrolyte ﬁlm and bonemay affect the hydrolysis rate of PLGA
and rather protect is from biodegradation. Having this information
in mind, we may anticipate that it would take at least about a year
for the PLGA to biodegrade. In this timeframe, the regenerated bone
would have been sufﬁciently formed and may not need any more a
mechanical support, in contrast to the initial time upon implanta-
tion where this was needed for the ﬁlm and initial anchor of bone
growth.
Altogether, our results show that it is the appropriate choice of
the 3D scaffold architecture in combination with the 2D bioactive
coatings that enables this impressive and tunable bone repair. The
PEM ﬁlm coating presented herein has several technological ad-
vantages that show promise for clinical applications and approval
by regulatory agencies.
One key advantage of our approach is that both the dose of BMP-
2 delivered by the ﬁlm-coating (2D) and the architecture or type of
3D scaffolds (3D) can be modulated and adapted independently of
each other. A potential disadvantage of the 2D ﬁlm-coating is that it
needs to be associated with a 3D scaffold and is not “free-standing”.
Thus, the scaffold design itself should ﬁrst be optimized before the
ﬁlm coating can be applied.
The ﬁlm is made by a simple self-assembly of biopolymers and
contained only one growth factor, BMP-2. The ﬁlm can be dried,
stored off-the-shelf and sterilized by g-irradiation [33], which is a
commonly used sterilization method for orthopedic implants.
Finally, HA, EDC and BMP-2 are components approved by the US
Food and Drug Administration (FDA) and the European Medicine
Agencies (EMA) for bone tissue engineering and the crosslinking of
collagenmatrices. PLL has also been approved for food applications.
Last but not least, thanks to the ﬁlm tunability, the BMP-2 dosemay
be modulated depending on the need (in vivo localization of the
bone defect and its size).
In view of the possibility to apply the ﬁlm on a large variety of
3D volumetric scaffolds, it may be envisioned to combine the ﬁlms
with different types of polymers or metallic alloy commonly used
in orthopedics, maxillofacial surgery, dentistry or veterinary med-
icine. Or particular interest are the recent developments in additive
manufacturing techniques [65,66], which have shown their broad
applicability to polymers such as polycaprolactone [12] or to
metallic alloy such as titanium [67]. The unprecedented potential-
ities offered by these innovative techniques to create a large variety
of scaffold shapes and architectures, combined with the new pos-
sibility to optimize the BMP-2 dose open new perspectives for
personalized medicine. As our ﬁrst proof of concept, we selected
here the commercially-available Lactosorb PLGA sheet as a
M. Bouyer et al. / Biomaterials 104 (2016) 168e181180polymeric scaffold, since Lactosorb it is already widely used in
clinics. Since we have already proved the possibility to coat TCP/
HAP granules [32] and titanium scaffolds [33] with the BMP-2
loaded ﬁlms, which were also shown to induce ectopic bone
growth, we foresee that ceramics and titanium scaffold could also
be, in a near future, combined with the osteoinductive coatings to
repair volumetric bone defects [68].
Our technology provides an alternative to conventional bone
grafts for the targeted repair of large bone defects using bioactive
PEM 2D surface coatings of 3D volumetric scaffolds. The next step
in view of its pre-clinical validation and clinical translation will
undoubtedly to prove its efﬁcacy in a larger animal model.
5. Conclusions
Using a polyelectrolyte ﬁlm loaded with tunable doses of BMP-2
as osteoinductive surface coating of a hollow PLGA tube, which was
initially fully empty, we show that the repair of a bone volumetric
defect is dependent on the amount of BMP-2 released by the
polyelectrolyte ﬁlm coating. Depending on the BMP-2 dose, a range
of responses, from no effect to rapid bone repair in 1 week, can be
achieved, including complete defect bridging and the formation of
vascularized and mineralized bone tissue. High-resolution
computed tomography revealed the presence of bone regenera-
tion inside and around the tube with spatially distinct organization
for trabecular-like and cortical bone. This efﬁcient way to trigger a
fast volumetric bone regeneration via the surface of an implant
opens perspectives for applications of these coatings in personal-
ized medicine. The simplicity and robustness of the present coating
is an advantage for its broad applicability for other bone repair
applications, since the bioactive surface coating can be adapted to
different types of materials (polymers, ceramics, metals) of any
topology, including architectured materials.
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